Assessment of the role of pharmacist to control blood glucose, blood pressure and lipid profile in type 2 diabetic patients

Study on A1c Management by Pharmacist in Lahore: A randomised controlled trial to assess the effectiveness of interventions by pharmacist in management of type 2 diabetes mellitus in collaboration with physician

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN22657497

Enrollment

350

Registered

2017-07-26

Start date

2016-03-20

Completion date

Unknown

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus Nutritional, Metabolic, Endocrine Type 2 Diabetes Mellitus

Interventions

The participants of this study are randomised according to individual patient's enrollment number i.e. the odd numbers were allocated to control arm and even numbers to intervention arm.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Either Male / Female 2. Resident of Lahore City 3. Age ?18 Years 4. Haemoglobin ?13mg/dL 5. Type 2 Diabetes Mellitus 6. Glycated Heamoglobin (HbA1c) ?8% i.e. poorly controlled 7. With or Without Hypertension (HTN) 8. With or Without Diabetic Nephropathy 9. With or Without Hepatosteatosis (Fatty Liver) 10. Without Psychosis and Cognitive Disorder 11. With or without Insulin use 12. No Pharmacist Involvement in Diabetes Management

Exclusion criteria

Exclusion criteria: 1. The patients with any other type of diabetes mellitus 2. Patients with Glycated Heamoglobin (HbA1c) ? 8% 3. Patients below age 18 years and above 70 years 4. Patients who refused to sign the consent form 5. Patients who showed no interest for future visit to study site and or participant physicians 6. Patient with cognitive and or psychotic disorders 7. Hospitalised Patients

Design outcomes

Primary

Measure	Time frame
1. Glycated Haemoglobin (HbA1c) is measured using the laboratory results from blood samples at baseline and three, six and nine months 2. Lipid profile is measured using laboratory results from blood samples at baseline, three, six, and nine months 3. Blood pressure is measured using the mercuric sphygmomanometer at baseline, three, six and nine months for both control and intervention arm patients and at every visit i.e. 4 weeks for intervention arm patients	—

Measure

Time frame

1. Glycated Haemoglobin (HbA1c) is measured using the laboratory results from blood samples at baseline and three, six and nine months 2. Lipid profile is measured using laboratory results from blood samples at baseline, three, six, and nine months 3. Blood pressure is measured using the mercuric sphygmomanometer at baseline, three, six and nine months for both control and intervention arm patients and at every visit i.e. 4 weeks for intervention arm patients

—

Secondary

Measure	Time frame
1. Height (m) is measured using a height rod at baseline, three, six and nine months 2. Weight (Kg) is measured using weighing balance at baseline, three, six and nine months 3. Waist (cm) is measured using measuring tape at baseline, three, six and nine months 4. Serum Creatinine (mg/dL) is measured using blood samples at baseline, three, six and nine months 5. Estimated Glomerular Filtration Rate (eGFR) is measured using Modification of Diet in Renal Disease (MDRD) Equation at baseline, three, six and nine months 6. Heamatology Report is measured using blood samples at baseline, three, six and nine months 7. Complete Urine Examination is measured using urine sample at baseline and six months 8. Foot Examination is measured using micro-monofilament and tunning fork at baseline, three, six and nine months	—

Measure

Time frame

1. Height (m) is measured using a height rod at baseline, three, six and nine months 2. Weight (Kg) is measured using weighing balance at baseline, three, six and nine months 3. Waist (cm) is measured using measuring tape at baseline, three, six and nine months 4. Serum Creatinine (mg/dL) is measured using blood samples at baseline, three, six and nine months 5. Estimated Glomerular Filtration Rate (eGFR) is measured using Modification of Diet in Renal Disease (MDRD) Equation at baseline, three, six and nine months 6. Heamatology Report is measured using blood samples at baseline, three, six and nine months 7. Complete Urine Examination is measured using urine sample at baseline and six months 8. Foot Examination is measured using micro-monofilament and tunning fork at baseline, three, six and nine months

—

Countries

Pakistan

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 2, 2026